Based on the significant prognostic value of E2F1 and E2F6 as well as their association with tumor stage and Gleason score in prostate cancer, we generated nomograms for predicting a patient’s 1-year, 3-year and 5-year relapse-free survival (Figure 4B). This evidence concerns the gene E2F1 and prostate carcinoma.